PE20120907A1 - Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato - Google Patents
Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamatoInfo
- Publication number
- PE20120907A1 PE20120907A1 PE2011001962A PE2011001962A PE20120907A1 PE 20120907 A1 PE20120907 A1 PE 20120907A1 PE 2011001962 A PE2011001962 A PE 2011001962A PE 2011001962 A PE2011001962 A PE 2011001962A PE 20120907 A1 PE20120907 A1 PE 20120907A1
- Authority
- PE
- Peru
- Prior art keywords
- xrpd
- peaks
- presenting
- methylsulfamate
- pirrolo
- Prior art date
Links
- FIYXUOWXHWJDAM-UHFFFAOYSA-N methyl sulfamate Chemical compound COS(N)(=O)=O FIYXUOWXHWJDAM-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21622109P | 2009-05-14 | 2009-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120907A1 true PE20120907A1 (es) | 2012-08-18 |
Family
ID=42396430
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001962A PE20120907A1 (es) | 2009-05-14 | 2010-05-13 | Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato |
| PE2016001604A PE20161222A1 (es) | 2009-05-14 | 2010-05-13 | Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001604A PE20161222A1 (es) | 2009-05-14 | 2010-05-13 | Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9187482B2 (enExample) |
| EP (2) | EP2430026A1 (enExample) |
| JP (3) | JP2012526808A (enExample) |
| KR (2) | KR20170102381A (enExample) |
| CN (2) | CN102421780A (enExample) |
| AU (1) | AU2010248151B2 (enExample) |
| BR (1) | BRPI1012142A2 (enExample) |
| CA (1) | CA2761256C (enExample) |
| IL (1) | IL216201A (enExample) |
| MX (1) | MX2011012108A (enExample) |
| NZ (2) | NZ596470A (enExample) |
| PE (2) | PE20120907A1 (enExample) |
| PH (1) | PH12015501925A1 (enExample) |
| RU (1) | RU2562245C2 (enExample) |
| SG (2) | SG10201402148SA (enExample) |
| UA (1) | UA108986C2 (enExample) |
| WO (1) | WO2010132110A1 (enExample) |
| ZA (1) | ZA201108347B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| CA2949336C (en) | 2007-08-02 | 2018-11-06 | Lei Zhu | Process for the synthesis of e1 activating enzyme inhibitors |
| CN102421780A (zh) | 2009-05-14 | 2012-04-18 | 米伦纽姆医药公司 | 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐 |
| US20120115892A1 (en) * | 2010-11-05 | 2012-05-10 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor |
| MY166889A (en) * | 2011-08-24 | 2018-07-24 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| KR101987861B1 (ko) | 2011-11-03 | 2019-06-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 |
| UA116534C2 (uk) | 2012-02-17 | 2018-04-10 | Мілленніум Фармасьютікалз, Інк. | Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту |
| US9593121B2 (en) | 2012-08-03 | 2017-03-14 | Millennium Pharmaceuticals, Inc. | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 |
| WO2014055543A2 (en) | 2012-10-01 | 2014-04-10 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
| EP2996773B1 (en) | 2013-05-14 | 2020-09-16 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
| EA032577B1 (ru) | 2013-07-02 | 2019-06-28 | Милленниум Фармасьютикалз, Инк. | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента |
| RS59474B1 (sr) | 2014-07-01 | 2019-12-31 | Millennium Pharm Inc | Heteroarilna jedinjenja koja su korisna kao inhibitori sumo-aktivirajućeg enzima |
| CN106008394B (zh) * | 2016-05-23 | 2018-12-04 | 中国人民解放军第二军医大学 | 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途 |
| JP2020534331A (ja) * | 2017-09-21 | 2020-11-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用 |
| JP2022521972A (ja) * | 2019-02-26 | 2022-04-13 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | アジュバントとして有用な化合物 |
| KR20210115680A (ko) | 2020-03-16 | 2021-09-27 | 서희강 | 연설용 프롬프터 |
| WO2022112951A1 (en) | 2020-11-25 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622561A (en) | 1969-08-18 | 1971-11-23 | Univ Utah | Nucleoside sugar esters of sulfamic acid and method for preparation of the same |
| US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
| JPS62108897A (ja) | 1985-11-05 | 1987-05-20 | Rikagaku Kenkyusho | アスカマイシン誘導体及びその合成法並びに制癌剤 |
| GB8813148D0 (en) | 1988-06-03 | 1988-07-06 | Glaxo Group Ltd | Chemical compounds |
| GB8826205D0 (en) | 1988-11-09 | 1988-12-14 | Wellcome Found | Heterocyclic compounds |
| US5726302A (en) | 1989-09-15 | 1998-03-10 | Gensia Inc. | Water soluble adenosine kinase inhibitors |
| US5864033A (en) | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| US5763596A (en) | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
| US5470898A (en) | 1993-06-30 | 1995-11-28 | Montell North America Inc. | Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith |
| GB9325809D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
| GB9325810D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
| US6210917B1 (en) | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
| US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US5973161A (en) | 1996-03-18 | 1999-10-26 | The University Of North Carolina At Chapel Hill | Enantioselective synthesis of cyclopentenes |
| US5824657A (en) | 1997-03-18 | 1998-10-20 | Cubist Pharmaceuticals, Inc. | Aminoacyl sulfamides for the treatment of hyperproliferative disorders |
| US6734283B1 (en) | 1997-12-19 | 2004-05-11 | Millennium Pharmaceuticals, Inc. | Human proteins responsible for NEDD8 activation and conjugation |
| JPH11228422A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
| JPH11228446A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
| EP1411954B1 (en) | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| EP1474147B1 (en) | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| WO2003106477A1 (en) | 2002-06-01 | 2003-12-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US7338957B2 (en) | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| US20090036448A1 (en) | 2004-03-30 | 2009-02-05 | Taisho Pharmecutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2006002284A1 (en) | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| EP1848718B1 (en) | 2005-02-04 | 2012-08-01 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| CN106008512B (zh) * | 2006-02-02 | 2019-03-12 | 千禧药品公司 | E1活化酶抑制剂 |
| NZ574513A (en) * | 2006-08-08 | 2012-02-24 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| CA2949336C (en) * | 2007-08-02 | 2018-11-06 | Lei Zhu | Process for the synthesis of e1 activating enzyme inhibitors |
| CN102421780A (zh) | 2009-05-14 | 2012-04-18 | 米伦纽姆医药公司 | 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐 |
| KR101987861B1 (ko) | 2011-11-03 | 2019-06-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 |
| EP2996773B1 (en) | 2013-05-14 | 2020-09-16 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
-
2010
- 2010-05-13 CN CN2010800213224A patent/CN102421780A/zh active Pending
- 2010-05-13 CN CN201410200959.XA patent/CN104016987A/zh active Pending
- 2010-05-13 PE PE2011001962A patent/PE20120907A1/es not_active Application Discontinuation
- 2010-05-13 JP JP2012510795A patent/JP2012526808A/ja not_active Withdrawn
- 2010-05-13 AU AU2010248151A patent/AU2010248151B2/en not_active Ceased
- 2010-05-13 PE PE2016001604A patent/PE20161222A1/es not_active Application Discontinuation
- 2010-05-13 KR KR1020177024122A patent/KR20170102381A/ko not_active Ceased
- 2010-05-13 EP EP10732492A patent/EP2430026A1/en not_active Withdrawn
- 2010-05-13 MX MX2011012108A patent/MX2011012108A/es not_active Application Discontinuation
- 2010-05-13 EP EP16159438.7A patent/EP3091020B1/en active Active
- 2010-05-13 SG SG10201402148SA patent/SG10201402148SA/en unknown
- 2010-05-13 CA CA2761256A patent/CA2761256C/en not_active Expired - Fee Related
- 2010-05-13 NZ NZ596470A patent/NZ596470A/en not_active IP Right Cessation
- 2010-05-13 RU RU2011150826/04A patent/RU2562245C2/ru not_active IP Right Cessation
- 2010-05-13 KR KR1020117029162A patent/KR20120024715A/ko not_active Ceased
- 2010-05-13 SG SG2011081957A patent/SG175929A1/en unknown
- 2010-05-13 US US12/779,331 patent/US9187482B2/en not_active Expired - Fee Related
- 2010-05-13 UA UAA201114830A patent/UA108986C2/uk unknown
- 2010-05-13 BR BRPI1012142A patent/BRPI1012142A2/pt not_active IP Right Cessation
- 2010-05-13 NZ NZ621128A patent/NZ621128A/en not_active IP Right Cessation
- 2010-05-13 WO PCT/US2010/001415 patent/WO2010132110A1/en not_active Ceased
-
2011
- 2011-11-08 IL IL216201A patent/IL216201A/en not_active IP Right Cessation
- 2011-11-14 ZA ZA2011/08347A patent/ZA201108347B/en unknown
-
2015
- 2015-01-16 JP JP2015006444A patent/JP2015096547A/ja not_active Withdrawn
- 2015-09-01 PH PH12015501925A patent/PH12015501925A1/en unknown
- 2015-10-09 US US14/879,151 patent/US10016427B2/en not_active Expired - Fee Related
-
2017
- 2017-02-08 JP JP2017020911A patent/JP2017105816A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120907A1 (es) | Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato | |
| Konno et al. | Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety | |
| AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| ES2723277T3 (es) | Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| CR11741A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| PE20121499A1 (es) | Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas | |
| PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
| AR087672A1 (es) | Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer | |
| SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
| CL2009000576A1 (es) | Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide. | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
| BR112015009850A2 (pt) | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase | |
| EA201070237A1 (ru) | Четвертичные опиоидные карбоксамиды | |
| EA201200507A1 (ru) | Применение активаторов никотинового ацетилхолинового рецептора альфа 7 | |
| EA201290397A1 (ru) | 1,3,4-оксадиазол-2-карбоксамидное соединение | |
| MA35451B1 (fr) | Dérivés de pyrrolopyrimidine et de purine | |
| CO6382122A2 (es) | Compuestos útiles para inhibir chk1 | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| DOP2011000362A (es) | Metodo para la preparacion de hidrocloruro de nalmefeno activo | |
| LU92282I2 (fr) | Telmisartan et/ou ses sels pharmacologiquement acceptables | |
| PE20080338A1 (es) | 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa) | |
| FR2936175B1 (fr) | Machine et procede d'usinage d'une piece par micro-electroerosion | |
| CO6382123A2 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| IN2012DN00765A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FD | Application declared void or lapsed |